Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Cost-Effectiveness of Paclitaxel plus Cisplatin as a Neoadjuvant Chemotherapy for Locally Advanced Head and Neck Cancer

국소진행성 두경부암에서 선행항암화학요법제로 사용되는 Paclitaxel과 Cisplatin 병용요법의 비용-효과성

  • Received : 2010.04.19
  • Accepted : 2010.06.21
  • Published : 2010.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

This study was conducted to analyze cost-effectiveness of neoadjuvant chemotherapy for locally advanced head and neck cancer in Korean healthcare setting. We constructed a decision analytical model to estimate total costs and outcomes of paclitaxel+cisplatin (PC) or docetaxel+cisplatin+5-FU (DCF) for 2 years time horizon in 100 patient cohort with locally advanced head and neck cancer. Base analysis showed that cost savings of PC regimen were 379 million Korean Won and 231 million Korean Won in societal and payer's perspectives, respectively, compared to DCF regimen, and life saved was 0.18. PC regimen as a dominant strategy was found to be robust through sensitivity analyses.

Keywords

References

  1. National Cancer Information Center. Korea Cancer Statistics 2000. Available at: http://cancer.go.kr. Accessed April 20, 2008.
  2. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 1. 2007. Available at: www.nccn.org. Accessed April 20, 2008.
  3. Licitra L, Vermorken JB. Is there still a role for neoadjuvant chemotherapy in head and neck cancer? Annals of Oncology 2004; 15: 7-11. https://doi.org/10.1093/annonc/mdh001
  4. Specenier PM, Vermorken. Neoadjuvant chemotherapy in head and neck cancer: Should it be revised? Cancer Letters 2007; 256: 166-77. https://doi.org/10.1016/j.canlet.2007.06.015
  5. 성인고형암치료임상연구센터. 두경부암 치료권고안. 2005.
  6. Adelstein DJ, LeBlanc M. Does Induction Chemotherapy Have a Role in the Management of Locoregionally Advanced Squamous Cell Head and Neck Cancer. J Clin Onco. 2006; 24: 2624-28. https://doi.org/10.1200/JCO.2005.05.3629
  7. Schrijvers D, Vermorken JB. Taxanes in the treatment of head and neck cancer. Current Opinion in Oncology 2005; 17: 218-24. https://doi.org/10.1097/01.cco.0000158735.91723.0e
  8. Lang K, Menzin J, Earle CC, Jacobson J, Hsu MA. The economic cost of squamous cell cancer of the head and neck: findings from linked SEER-Medicare data. Arch Otolaryngol Head Neck Surg 2004; 130: 1269-75. https://doi.org/10.1001/archotol.130.11.1269
  9. Therasse P, Arbuck S, Eisenhauer E, et al., New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16. https://doi.org/10.1093/jnci/92.3.205
  10. Vermorken JB, Remenar E, Herpen CV, Gorlia T, Mesia R, Degardin M, et al., Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer. N Engl J Med 2007; 357: 1695-704. https://doi.org/10.1056/NEJMoa071028
  11. 식품의약품안전청. 의약품정보. Available at: http:// ezdrug.kfda.go.kr/kfda2. Accessed July 20, 2009.
  12. Bristol-Myers Squibb Company. A Phase 2 Trial of Neoadjuvant Paclitaxel and Cisplatin in Patients with Locally Advanced Head and Neck Cancer. Final Clinical Study Report for Study CA139384. October 24, 2007.
  13. Kim H, Han JY, Kang JH, Song HC, Moon HL, Hong YS, et al., Induction Chemotherapy using 5-FU and Cisplatin and Radiotherapy in Patients with Locally Advanced Head and Neck Cancer. 대한내과학회지 1995; 49(4): 484-91.
  14. Cho EK, Lee WS, Jung CW, Lee KS, Kim WS, Lee KH, Heo DS, et al., Combination Chemotherapy with 5- Fluorouracil and Carboplatin for Advanced Head and Neck Cancer. Joural of Korean Cancer Association 1996; 28(1): 95-103.
  15. Dunphy FR, Dunleavy TL, Harrison BR, Trinkaus KM, Kim HJ, Stack Jr BC, Needles B, Boyd JH. Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Cancer 2001; 91: 940-48. https://doi.org/10.1002/1097-0142(20010301)91:5<940::AID-CNCR1083>3.0.CO;2-A
  16. Cho E, Cho K, Song Y, Choi I, Choi J, Nam S, et al., Docetaxel and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Cancer. 대한두경부종양학회지 2005; 21(2): 126-31.
  17. Rapidis AD, Trichas M, Stavrinidis E, Roupakia A, Loannidou G, Kritselis G, et al., Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up. Oral oncology 2006; 42: 675-84. https://doi.org/10.1016/j.oraloncology.2005.12.006
  18. Posner MR. Paradigm shift in the treatment of head and neck cancer: the role of neoadjuvant chemotherapy. Oncologist 2005; 10(Suppl3): 11-19. https://doi.org/10.1634/theoncologist.10-90003-11
  19. 건강보험심사평가원. 약제급여목록 및 상한금액표. 2008년 6월.
  20. 건강보험심사평가원. 의약품 주성분별 가중평균가격 - 2008년 하반기. 2009년 2월.
  21. Mosteller RD. Simplified calculation of body surface area. N Engl J Med. 1987; 317(17): 1098.
  22. 대한의사협회. 건강보험요양급여비용 2008년 1월판.
  23. 보건복지부한국보건사회연구원. 국민건강영양조사 제3기 (2005), 2006. 7.
  24. 노동부. 임금구조 기본통계조사 보고서 2007년판.
  25. Patrick DL, Erickson P. Health status and health policy : quality of life in health care evaluation and resource allocation. New York: Oxford University Press; 1993.